29786-40-1

Usage

Structure

A cyclobutane ring fused with a tolyl group (3-methylphenyl) and a carbonitrile group (C≡N)

Type of compound

Nitrile derivative of cyclobutane

Cycloalkane

A four-membered ring (cyclobutane)

Applications

a. Building block in organic synthesis
b. Potential pharmaceutical properties
c. Synthesis of pharmaceuticals and agrochemicals
d. Material science and other fields

Unique properties

Valuable tool in the development of new chemical compounds and materials due to its structure and properties.

Upstream product

• 2947-60-6 3-methylbenzyl cyanide 
• 109-64-8 1,3-dibromo-propane 

Downstream Products

• 29786-31-0 <(1-m-Tolylcyclobutyl)carbonyl>carbamsaeureethylester 
• 29786-20-7 <(1-m-Tolylcyclobutyl)carbonyl>carbamsaeuremethylester 
• 29770-37-4 <1-(m-Tolylcyclobutyl)-carbonyl>-harnstoff 
• 29786-61-6 1-(m-Tolylcyclobutyl)-carbonylisocyanat 
• 29786-50-3 1-(m-tolyl)cyclobutane-1-carboxamide 

Relevant academic research and scientific papers

Oxadiazole Amine Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same

The present invention relates to a novel compound having an activity of inhibiting histone deacetylase 6 (HDAC6), an optical isomer thereof or a pharmaceutically acceptable salt thereof, a use thereof for preparation of a drug for treatment, a pharmaceutical composition comprising the same, a treatment method using the composition, and a method for preparing the same. The novel compound, an optical isomer thereof or a pharmaceutically acceptable salt thereof according to the present invention has an activity of inhibiting histone deacetylase 6 (HDAC6), and is effective for preventing or treating HDAC6-related diseases, including infectious diseases; neoplasm; endocrine, nutritional and metabolic diseases; mental and behavior disorders; nerve disorders; eye and adnexa diseases; cardiovascular diseases; respiratory diseases; digestive organ diseases; skin and subcutaneous tissue diseases; musculoskeletal and connective tissue diseases; or congenital malformation, deformation and chromosomal abnormality.COPYRIGHT KIPO 2017

NOVEL TRPV3 MODULATORS

Disclosed herein are modulators of TRPV3 of formula (I) wherein G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, u, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

NOVEL TRPV3 MODULATORS

Disclosed herein are modulators of TRPV3 of formula (I), wherein G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, u, and p are as defined in the specifica